Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Regorafenib
État du projet:
Terminé
Domaine thérapeutique:
Gastrointestinal Stromal Tumour
Fabricant:
Bayer Inc.
Brand Name:
Stivarga (GIST)
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0034-000
Strength:
40 mg Tablets
Tumour Type:
Other
Indications:
Gastrointestinal Stromal Tumours
Funding Request:
Treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumours (GIST) who have had disease progression on or intolerance to imatinib mesylate, and sunitinib malate treatment
Review Status:
Complete
Date NOC Issued:
Sponsor:
Bayer Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting (target date):
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016